Michele M Kim Selected Research

Fibrosarcoma

1/2020	1O2 determined from the measured PDT dose and 3O2 predicts long-term response to Photofrin-mediated PDT.
1/2017	Evaluation of singlet oxygen explicit dosimetry for predicting treatment outcomes of benzoporphyrin derivative monoacid ring A-mediated photodynamic therapy.
1/2017	A Comparison of Dose Metrics to Predict Local Tumor Control for Photofrin-mediated Photodynamic Therapy.
12/2016	Evaluation of the 2-(1-Hexyloxyethyl)-2-devinyl pyropheophorbide (HPPH) mediated photodynamic therapy by macroscopic singlet oxygen modeling.
2/2016	Dosimetry study of PHOTOFRIN-mediated photodynamic therapy in a mouse tumor model.
2/2016	Investigating the impact of oxygen concentration and blood flow variation on photodynamic therapy.
1/2016	Macroscopic singlet oxygen modeling for dosimetry of Photofrin-mediated photodynamic therapy: an in-vivo study.
3/2015	In vivo outcome study of BPD-mediated PDT using a macroscopic singlet oxygen model.
3/2015	Macroscopic singlet oxygen model incorporating photobleaching as an input parameter.
2/2015	In-vivo singlet oxygen threshold doses for PDT.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michele M Kim Research Topics

Disease

25	Neoplasms (Cancer) 01/2022 - 02/2013
13	Fibrosarcoma 01/2020 - 03/2014
8	Necrosis 11/2016 - 02/2013
7	Malignant Mesothelioma 09/2020 - 03/2015
4	Mesothelioma 01/2020 - 02/2013
2	Sarcoma (Soft Tissue Sarcoma) 01/2022 - 01/2021
2	AIDS-Related Complex (ARC) 01/2020 - 11/2018
1	Hypoxia (Hypoxemia) 01/2022
1	Adenocarcinoma 10/2021
1	Esophageal Neoplasms (Esophageal Cancer) 10/2021
1	Breast Neoplasms (Breast Cancer) 01/2021
1	Head and Neck Neoplasms (Head and Neck Cancer) 01/2021
1	Thymoma (Thymic Carcinoma) 01/2020
1	Prostatic Neoplasms (Prostate Cancer) 02/2015
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 03/2014

Drug/Important Bio-Agent (IBA)

24	1-phenyl-3,3-dimethyltriazene (PDT)IBA 01/2020 - 02/2013
13	Singlet OxygenIBA 01/2020 - 02/2013
9	Photosensitizing Agents (Photosensitizers)IBA 01/2020 - 02/2013
6	Oxygen (Dioxygen)IBA 01/2022 - 02/2016
6	2-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a (HPPH)IBA 12/2016 - 03/2014
5	Protons (Proton)IBA 01/2022 - 01/2019
5	Dihematoporphyrin Ether (Porfimer Sodium)FDA Link 01/2020 - 01/2016
2	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2020 - 02/2018
2	Verteporfin (Visudyne)FDA Link 01/2017 - 03/2015
2	Pharmaceutical PreparationsIBA 01/2017 - 01/2017
1	Biological ProductsIBA 01/2020
1	ElementsIBA 02/2016
1	pyropheophorbide aIBA 03/2015
1	temoporfinIBA 02/2015
1	Hematoxylin (Haematoxylon)IBA 03/2014
1	Eosine Yellowish-(YS) (Eosin)IBA 03/2014

Therapy/Procedure

15	Photochemotherapy (Photodynamic Therapy) 01/2020 - 02/2013
9	Radiotherapy 01/2022 - 11/2018
4	Proton Therapy 10/2021 - 01/2019
4	Therapeutics 10/2021 - 11/2018
3	Lasers (Laser) 01/2017 - 02/2016
2	Particle Accelerators 09/2020 - 09/2020
1	Chemoradiotherapy 10/2021
1	Drug Therapy (Chemotherapy) 10/2021
1	Aftercare (After-Treatment) 02/2018